SCHEMBL5079142

SCHEMBL5079142

COC(=O)CCCCCCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 1/20 0.47
LMNA P02545 1/20 0.43
PPARG P37231 2/20 0.42
PTPRC P08575 1/20 0.40
PTPN13 Q12923 1/20 0.40
MAPT P10636 1/20 0.40
PPARA Q07869 1/20 0.40
FAAH O00519 1/20 0.40
TBXAS1 P24557 1/20 0.39
CNR2 P34972 1/20 0.39
HDAC3 O15379 3/20 0.39
HDAC4 P56524 3/20 0.39
HDAC1 Q13547 3/20 0.39
HDAC7 Q8WUI4 3/20 0.39
HDAC2 Q92769 3/20 0.39
HDAC10 Q969S8 3/20 0.39
HDAC11 Q96DB2 3/20 0.39
HDAC8 Q9BY41 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
HDAC9 Q9UKV0 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26100458 0.94 LMNA (0.42) LTB4RLMNAMAPTTBXAS1CNR2
SCHEMBL14265500 0.93 TBXAS1 (0.42) LTB4RLMNAPPARGPPARAFAAH
SCHEMBL19331603 0.90 PPARG (0.43) LTB4RLMNAPPARGPPARATBXAS1
SCHEMBL16705775 0.90 TBXAS1 (0.40) LTB4RLMNAPPARGPPARAFAAH
SCHEMBL1291773 0.89 LMNA (0.40) LTB4RLMNAMAPTALDH1A1SMN1; SMN2
SCHEMBL30887240 0.87 TBXA2R (0.43) LTB4RMAPTPPARATBXAS1HDAC3
SCHEMBL31528916 0.87 TBXA2R (0.43) LTB4RMAPTPPARATBXAS1HDAC3
SCHEMBL31528895 0.87 TBXA2R (0.43) LTB4RMAPTPPARATBXAS1HDAC3
SCHEMBL19405748 0.87 TBXA2R (0.43) LTB4RMAPTPPARATBXAS1HDAC3
SCHEMBL28691927 0.87 TBXA2R (0.43) LTB4RMAPTPPARATBXAS1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971347-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS Tika Läkemedel AB (SE) 2008-09-24 EP claimed
WO-2007075798-A9 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS HAVING AN INCREASED LUNG DEPOSITION VERUS PHARMACEUTICALS INC (US) 2007-08-23 WO claimed
WO-2007075800-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS TIKA LÄKEMEDEL AB (SE) 2007-07-05 WO claimed
EP-1973550-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS HAVING AN ENHANCED PHARMACOKINETIC PROFILE Tika Läkemedel AB (SE) 2008-10-01 EP disclosed
EP-1971346-A2 SYSTEMS AND METHODS FOR THE DELIVERY OF CORTICOSTEROIDS Tika Läkemedel AB (SE) 2008-09-24 EP disclosed
EP-1971347-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS Tika Läkemedel AB (SE) 2008-09-24 EP disclosed
US-7348173-B2 Fatty-acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2008-03-25 US disclosed
EP-0970195-B1 FATTY-ACID AMIDE HYDROLASE SCRIPPS RESEARCH INST (US) 2007-10-17 EP disclosed
WO-2007075799-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS HAVING AN ENHANCED PHARMACOKINETIC PROFILE TIKA LÄKEMEDEL AB (SE) 2007-07-05 WO disclosed
WO-2007075800-A2 METHODS AND SYSTEMS FOR THE DELIVERY OF CORTICOSTEROIDS TIKA LÄKEMEDEL AB (SE) 2007-07-05 WO disclosed
WO-2007075963-A2 SYSTEMS AND METHODS FOR THE DELIVERY OF CORTICOSTEROIDS TIKA LÄKEMEDEL AB (SE) 2007-07-05 WO disclosed
US-20020187542-A1 Fatty-acid amide hydrolase THE SCRIPPS RESEARCH INSTITUTE (US) 2002-12-12 US disclosed
EP-0970195-A4 FATTY-ACID AMIDE HYDROLASE SCRIPPS RESEARCH INST (US) 2001-12-05 EP disclosed
US-6271015-B1 A POLYPEPTIDE HAVING AN AMINO ACID SEQUENCE THAT HYDROLYSIZES CIS-9,10-OCTADECENOAMIDE AND OTHER SOPORIFIC FATTY ACID AMIDES; THERAPY FOR SLEEP DISORDERS AND NARCOLEPSY THE SCRIPPS RESEARCH INSTITUTE 2001-08-07 US disclosed
EP-0833899-A4 CIS-9,10-OCTADECENOAMIDASE SCRIPPS RESEARCH INST (US) 2000-06-28 EP disclosed
EP-0970195-A1 FATTY-ACID AMIDE HYDROLASE The Scripps Research Institute (US) 2000-01-12 EP disclosed
WO-1998020119-A9 FATTY-ACID AMIDE HYDROLASE 1998-11-05 WO disclosed
WO-1998020119-A1 FATTY-ACID AMIDE HYDROLASE THE SCRIPPS RESEARCH INSTITUTE (US) 1998-05-14 WO disclosed
EP-0833899-A1 CIS-9,10-OCTADECENOAMIDASE THE SCRIPPS RESEARCH INSTITUTE (US) 1998-04-08 EP disclosed
WO-1996041869-A1 CIS-9,10-OCTADECENOAMIDASE THE SCRIPPS RESEARCH INSTITUTE (US) 1996-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020187542-A1 Fatty-acid amide hydrolase FAAH, FAAH2, APEH LTB4R 1947/4885LMNA 3794/4885PPARG 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.